FDA advisers who voted against the approval of Biogen’s Alzheimer’s disease drug aducanumab have reiterated their objections in a JAMA article. The article restates the case against aducanumab ahead of a June decision by the FDA on whether to approve the controversial, closely watched medicine.

Cancer metabolism-focused Tyme Technologies signed a new acting chief medical officer four months after it shuffled its C-suite to make room for a new CEO. Jan Van Tornout, M.D., arrives after holding positions in both biopharma and academia and replaces Giuseppe del Priore, M.D.

Eloxx Pharmaceuticals had a tough 2020, starting out the year cutting staffers and hiring a new chief, and then had a stop-start relationship with its midstage cystic fibrosis trial amid COVID-19 chaos.

President Joe Biden has proposed pumping tens of billions of dollars into R&D through his American Jobs Plan. The plan includes $30 billion of pandemic-related spending intended to accelerate drug development and otherwise help the U.S. recover from COVID-19 and prevent future crises.

Scribe Therapeutics is adding another $100 million to its coffers six months after unveiling a $20 million series A and a partnership with Biogen to work on gene editing treatments for amyotrophic lateral sclerosis (ALS). The new funds will support the development of the company’s gene editing and delivery technologies and propel a pipeline of treatments for neurodegeneration and other diseases.

Entrada Therapeutics has raised $116 million to develop intracellular biologics. The series B round will enable Entrada to start clinical development of a pipeline featuring treatments for diseases such as Duchenne muscular dystrophy (DMD).

Flagship Pioneering has named Michael Nally as CEO-partner. The venture capital shop has put the former Merck executive in charge of machine-learning-enabled drug discovery play Generate Biomedicines.

Tyra Biosciences raised $50 million in early 2020 to get the ball rolling on a pipeline against drug-resistant cancers. Now, the company is gearing up to see its first program into clinical trials, and it’s banking $106 million and expanding its leadership team to get there.

It’s been a nice month for Pyxis Oncology: After penning a major licensing deal with Pfizer, the startup now has $152 million extra in the bank to help it push on with its expanded pipeline.

Omega Therapeutics is taking it up a notch. The “genome-tuning” biotech raised $126 million to get its lead program, a treatment for liver cancer, into the clinic as well as to advance a clutch of other preclinical prospects including a treatment for acute respiratory distress syndrome (ARDS), a life-threatening lung injury that can result from COVID-19 infection.